Hepatoprotective effect of diheptanoin and tritreptanoin chronic consumption against steatosis in rats;Efeito hepatoprotetor do consumo crônico de dieptanoína e trieptanoína contra a esteatose em ratos

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 7, 2008, Pages 1145-1155

  Da Silva, Maria A Firmino ^a,c   Da R Ataide, Terezinha ^a   De Oliveira, Suzana L ^a   Sant'Ana, Antonio E G ^b   Cabral Jr , Cyro R ^a   Balwani, Maria Do C L V ^a   De Oliveira, Fernanda G S ^c   Santos, Mércia C ^c  

^a FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^b Instituto de Química e Biotecnologia   (Brazil)

^c NONE

Author keywords

Diheptanoin; Hepatic steatosis; Triheptanoin

Indexed keywords

CHOLESTEROL; DIACYLGLYCEROL; LIPID; TRIACYLGLYCEROL; TRIHEPTANOIN;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; FATTY LIVER; GLUCOSE BLOOD LEVEL; KIDNEY; MALE; PATHOLOGY; RAT; REGRESSION ANALYSIS; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; DIGLYCERIDES; FATTY LIVER; KIDNEY; LIPIDS; MALE; RATS; RATS, WISTAR; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 58149176740     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302008000700011     Document Type: Article

References (40)

1. Arrospide MT. Hígado graso no alcohólico. Rev Gastroenterol Peru. 2003;23(1):49-57.
2. Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lowerfatdiet in patients with NAFLD. Am J Gastroenterol. 2006;101(10):2247-53.
3. Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, Carvalho FM, Freitas LA, Barreto D, et ai. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol. 2005; 17(8):837-41.
4. McCullough A. Update on nonalcoholic fatty liver disease. J. Clin Gastroenterol. 2002;34(3):255-62.
5. Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2(1):46-53.
6. Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis. 2007;17(1):63-70.
7. Herselman MG, Labadarios D, Rensburg CJV, Haffejee AA. Nutrição nas doenças do fígado. In: Gibney MJ, Elia, M, Ljungqvist O, Dowsett J, editors. Nutrição clínica. Rio de Janeiro: Guanabara Koogan; 2007. p. 150-76.
8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31.
9. Poonawala A, Nair SP, Thuluvath P. Prevalence of obesity and diabetes in patients wich cryptogenetic cirrhosisa case-con-trol study. Hepatology. 2000;32:689-92.
10. Caldwell SH, Oelsner DH, Lezzoni JC, Hespenheide EE, Battle EH, Drscoel CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underliing disease. Hepatology. 1999;661-9.
11. Nagao K, lnoue N, Wang YM, Shirouchi B, Yanagita T. Dietary Conjugated Linoleic Acid Alleviates Nonalcoholic Fatty Liver Disease in Zucker (fa/fa) Rats. J Nutr. 2005;135:9-13.
12. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. Can Med Assoc J. 2005;172:899-905.
13. Poniachik TJ, Mancilla CA, Contreras JB, Csendes AJ, Smok GS, Cavada GCH, et al. Obesidad: factor de riesgo para esteatohepatitis y fibrosis hepática. Rev Med Chil. 2002;130:731-6.
14. Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2(3): 148-55.
15. Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006;40(3):39-43.
16. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279(31):32345-53.
17. Barreiro MAA, Villar MEA, Suazo FM. Trigliceridos de cadena media en el tratamiento de obesidad. Rev Salud Publ Nutrie [periódico na Internet]. 2004 [acesso em 2004 Dec 10] 5(2). Disponí vel em: http://www.respyn. uanl.mx/v/2/articulos/art.tcm.htm.
18. Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002;110(2):259-69.
19. Mochel F, Pascale DGT, Henri B, Kiman RP, Robier D, Chales R, et al. Pyruvate carboxilase deficiency: clinical and biochemical response to anaplerotic diettrerapy. MoI Genet Metab. 2004;84:305-2.
20. Ataide, TR, Lima, MRF, Valentim, IB, Pinheiro, DM, Sant'Ana, AEG. Chemical synthesis of tricaproin, trienantin and tricaprylin. lnt J Food Sci Technol. 2007;42:1504-8.
21. Reeves PG. Components of the AIN-93 diets as improvements in the AIN-76 a diet. J Nutr. 1997;127(5):838-41.
22. Hoffman WA, Pons JA, Janer JL. Sedimentation concentration method in schistosomiasis mansoni. J Publ Health Trop Med. 1934;9:283-98.
23. Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low density lipoproteins cholesterol in plasma without use of the ultracentrifuge. Clin Chem. 1972;18:499-502.
24. Bligh EG, Dyer WJ. A rapid method of total lipid extration and purification. Can J Biochem Physiol. 1959;37:911-7.
25. Ferreira AMD, Barbosa PEB, Ceddia RB. A influência da suplementação de triglicerídeos de cadeia média no desempenho em exercícios de ultra-resistência. Rev Bras Med Esporte. 2003;9(6):413-9.
26. Reis KAA, Roquete MLV, Penna FJ. Esteatohepatite näo- alcoólica na infancia e adolescência: revisão. Pediatria. 2001;23(4): 329-39.
27. Day CP, James OFW. Steatohepatitis a tale of two "hits"? Gastroenterology. 1998;114:842-4.
28. Chitturi S, Abeygunasekera S, Farrell, GC. NASH and insulin resistence: insulin hipersecretions and association with the insulin syndrome. Hepatology. 2001;35(2):373-9.
29. Busetto L, Tregnaghi A, Marchi F, Segato G, Foletto M, Sergi G, et al. Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding. Obes Res. 2002;10(5):408-11.
30. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722-8.
31. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistence and mitocondrial abnormalities. Gastroenterology. 2001;120:1183-92.
32. Ribeiro Filho FF, Mariosa LS, Ferreira SRG, Zanella MT. Gordura visceral e síndrome metabólica: mais que uma simples associaçã o. Arq Bras Endocrinol Metab. 2006;50(2):230-8.
33. Eckel RH, Hanson AS, Chen Ay, Berman JN, Yost TJ, Brass EP. Dietary substitution of medium chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects. Diabetes. 1992;41:641-7.
34. Parise ER, Santos VN. Importância clínica da esteatose hepá tica. In: Castro LP, Savassi-Rocha PR, Galizzi Filho J, Lima AS, editores. Tópicos em Gastroenterologia. 9. ed. Belo Horizonte; 1999. p. 473-8.
35. Gauthier MS, Favier R, Lavoie JM. Time course of the development of non-alcoholic hepatic steatosis in response to highfat diet-induced obesity in rats. BrJ Nutr. 2006;95(2):273-81.
36. Harkness JE, Wagner EJ. Biologia Clínica de Coelhos e Roedores. 3. ed. São Paulo: Ed. Roca; 1993.
37. Murray RK, Granner DK, Mayes PA, Rodwell VW. Harper: Bioquímica. 7. ed. São Paulo: Atheneu; 1994.
38. Ockner RK. Doenças do fígado, da vesícula biliar e dos duetos biliares. In: Wyngaarden JB, editor. Tratado de Medicina Interna. Rio de Janeiro: Guanabara Koogan; 1993.
39. Motta VT. Bioquímica Clínica para o Laboratório: Princípios e Interpretações. Porto Alegre: Ed. Médica Missau; São Paulo: Robe Editorial; 2003.
40. Ravel R. Laboratório clínico. Aplicações Clínicas dos Dados Laboratoriais. 6. ed. Rio de Janeiro: Guanabara Koogan; 1997.